H.M. El Tayebi

637 total citations
37 papers, 499 citations indexed

About

H.M. El Tayebi is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, H.M. El Tayebi has authored 37 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 17 papers in Cancer Research and 13 papers in Oncology. Recurrent topics in H.M. El Tayebi's work include Cancer-related molecular mechanisms research (13 papers), MicroRNA in disease regulation (10 papers) and Immune cells in cancer (6 papers). H.M. El Tayebi is often cited by papers focused on Cancer-related molecular mechanisms research (13 papers), MicroRNA in disease regulation (10 papers) and Immune cells in cancer (6 papers). H.M. El Tayebi collaborates with scholars based in Egypt, Germany and Netherlands. H.M. El Tayebi's co-authors include Ahmed Ihab Abdelaziz, Gamal Esmat, Karim Adel Hosny, Ulrike Stein, R.A. Assal, Heba Handoussa, Kai Breuhahn, Ahmed H. El‐Khatib, Michael Linscheid and R.A. Youness and has published in prestigious journals such as Biochemical and Biophysical Research Communications, FEBS Letters and International Journal of Molecular Sciences.

In The Last Decade

H.M. El Tayebi

35 papers receiving 494 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.M. El Tayebi Egypt 15 328 287 88 80 52 37 499
Chaoliang Liao China 12 326 1.0× 226 0.8× 40 0.5× 80 1.0× 74 1.4× 13 492
Xuan Zhu China 15 339 1.0× 273 1.0× 44 0.5× 91 1.1× 50 1.0× 28 519
Baojia Zou China 14 361 1.1× 291 1.0× 56 0.6× 118 1.5× 76 1.5× 28 575
Pei Li China 15 427 1.3× 337 1.2× 40 0.5× 71 0.9× 40 0.8× 27 581
Xiali Tang China 10 370 1.1× 262 0.9× 34 0.4× 97 1.2× 33 0.6× 14 547
Ya Juan Yao United States 6 345 1.1× 184 0.6× 56 0.6× 116 1.4× 66 1.3× 8 544
Mingrong Cao China 15 425 1.3× 271 0.9× 52 0.6× 82 1.0× 68 1.3× 41 611
Danyu Du China 9 430 1.3× 324 1.1× 93 1.1× 111 1.4× 109 2.1× 13 698
Yali Cao China 14 330 1.0× 269 0.9× 42 0.5× 140 1.8× 50 1.0× 38 617

Countries citing papers authored by H.M. El Tayebi

Since Specialization
Citations

This map shows the geographic impact of H.M. El Tayebi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.M. El Tayebi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.M. El Tayebi more than expected).

Fields of papers citing papers by H.M. El Tayebi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.M. El Tayebi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.M. El Tayebi. The network helps show where H.M. El Tayebi may publish in the future.

Co-authorship network of co-authors of H.M. El Tayebi

This figure shows the co-authorship network connecting the top 25 collaborators of H.M. El Tayebi. A scholar is included among the top collaborators of H.M. El Tayebi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.M. El Tayebi. H.M. El Tayebi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tayebi, H.M. El, et al.. (2024). Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy. Expert Reviews in Molecular Medicine. 26. e18–e18. 4 indexed citations
2.
3.
Tayebi, H.M. El, et al.. (2023). Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients. International Journal of Molecular Sciences. 24(18). 14254–14254. 3 indexed citations
4.
Tayebi, H.M. El, et al.. (2023). Inflammasomes in breast cancer: the ignition spark of progression and resistance?. Expert Reviews in Molecular Medicine. 25. e22–e22. 6 indexed citations
5.
Stein, Ulrike, et al.. (2022). The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer. Cancers. 14(21). 5460–5460. 29 indexed citations
6.
Stein, Ulrike, et al.. (2022). Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Molecules. 27(17). 5537–5537. 23 indexed citations
7.
Tayebi, H.M. El, et al.. (2022). CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer. Frontiers in Pharmacology. 13. 862125–862125. 18 indexed citations
8.
Bruyn, Marco de, et al.. (2022). NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer. Life Sciences. 299. 120523–120523. 4 indexed citations
9.
Tayebi, H.M. El, et al.. (2022). A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach. Frontiers in Molecular Biosciences. 9. 1032517–1032517. 16 indexed citations
10.
Stein, Ulrike, et al.. (2021). Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?. Cells. 10(2). 302–302. 19 indexed citations
11.
Handoussa, Heba, et al.. (2021). Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology. Life Sciences. 277. 119353–119353. 22 indexed citations
12.
Tayebi, H.M. El, et al.. (2020). GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets. Frontiers in Oncology. 10. 537311–537311. 17 indexed citations
13.
Tayebi, H.M. El, et al.. (2020). XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. Frontiers in Oncology. 9. 1459–1459. 43 indexed citations
14.
15.
Assal, R.A., Karim Adel Hosny, H.M. El Tayebi, et al.. (2019). Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Frontiers in Physiology. 9. 1918–1918. 18 indexed citations
16.
Handoussa, Heba, R.A. Youness, R.A. Assal, et al.. (2017). Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Natural Product Research. 32(18). 2217–2220. 54 indexed citations
17.
Tayebi, H.M. El, et al.. (2015). Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncology Letters. 10(5). 3206–3212. 23 indexed citations
18.
19.
Tayebi, H.M. El, Khalid Omar, Mohamed A. El-Brolosy, et al.. (2013). Repression of miR-17-5p with elevated expression of E2F-1 and c-MYC in non-metastatic hepatocellular carcinoma and enhancement of cell growth upon reversing this expression pattern. Biochemical and Biophysical Research Communications. 434(3). 421–427. 24 indexed citations
20.
Tayebi, H.M. El, Karim Adel Hosny, Gamal Esmat, Kai Breuhahn, & Ahmed Ihab Abdelaziz. (2012). miR‐615‐5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Letters. 586(19). 3309–3316. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chaoliang Liao Breakdown of academic impact, for papers by Xuan Zhu Breakdown of academic impact, for papers by Baojia Zou Breakdown of academic impact, for papers by Pei Li Breakdown of academic impact, for papers by Xiali Tang Breakdown of academic impact, for papers by Ya Juan Yao Breakdown of academic impact, for papers by Mingrong Cao Breakdown of academic impact, for papers by Danyu Du Breakdown of academic impact, for papers by Yali Cao
Rankless by CCL
2026